Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

ALK-positive NSCLC × ceritinib × Thoracic × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 20 Lung Neoplasms 7 Adenocarcinoma of Lung 4 Neoplasms 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1 Brain Neoplasms 1 ALK-positive Non-small Cell Lung Cancer 1 ALK-positive NSCLC 1

Interventions

Crizotinib 2 lorlatinib 1 ceritinib 1 brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

549 enrolled 28 charts

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡